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Abstract
Context: Growth hormone (GH) has been approved for children with Prader-Willi 
syndrome (PWS) and significantly improves body composition in adults with PWS. 
Adults with PWS are predisposed to develop impaired glucose tolerance (IGT) and 
diabetes mellitus type 2 (DMT2). Continuation of GH maintains body composition, 
but GH is known to induce insulin resistance, which might affect glucose homeosta-
sis. Studies on long-term effects of GH treatment in adults are very limited.
Objective: To investigate effects of 3 years of GH treatment on glucose homeostasis 
and prevalence of metabolic syndrome (MS) in adults with PWS.
Design: Open-label, prospective study.
Patients: 43 young adults with PWS.
Setting: Dutch PWS Reference Center.
Main outcome measures: Glucose and insulin during oral glucose tolerance test.
Results: Estimated mean (95% CI) fasting glucose and insulin levels remained stable 
during 3 years of GH treatment. Glucose being 4.6 (4.4-4.8) mmol/l at start and 4.7 
(4.6-4.9) mmol/l after 3 years (P = .07); insulin being 59.5 (45.2-75.8) pmol/l and 56.7 
(45.2-69.6) pmol/l resp. (P = .72). Sex, ethnicity and fat mass percentage were sig-
nificantly associated with fasting glucose levels, while IGF-I or GH-dose were not. 
Blood pressure, lipids and prevalence of MS remained stable during 3 years of GH. 
IGT prevalence was variable over time, six patients had IGT at start and eleven after 
3 years of GH. One patient developed DMT2. However, prevalence of IGT or DMT2 
was not significantly higher after 3 years than at study start.
Conclusions: Three years of GH treatment in adults with PWS does not impair glu-
cose homeostasis and does not lead to an increased prevalence of DMT2.
K E Y W O R D S
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1  | INTRODUC TION
Prader-Willi syndrome (PWS) is a rare multisystem genetic disor-
der caused by lack of expression of paternally inherited imprinted 
genes on the Prader-Willi region of chromosome 15, mostly caused 
by a paternal deletion or maternal uniparental disomy (mUPD) and 
in some cases by an imprinting centre defect (ICD) or paternal chro-
mosomal translocation.1,2 PWS is characterized by muscular hypo-
tonia, developmental delay, behavioural problems, short stature and 
hyperphagia which can result in severe obesity when food intake is 
uncontrolled.2,3 Body composition is abnormal with a high body fat 
percentage and a low lean body mass (LBM).4,5
In children with PWS, benefits of growth hormone (GH) treat-
ment are well established.4 GH improves body composition, psy-
chomotor development, cognition, adaptive functioning and linear 
growth4,6-8 without adverse effects on glucose parameters, lipid 
profile and blood pressure.4,9 GH treatment together with multidis-
ciplinary care from a young age onwards has substantially changed 
the phenotype of children with PWS.4,10
Currently, young adults with PWS have to cease GH treatment 
at attainment of adult height (AH), if they do not meet the criteria 
for adult growth hormone deficiency. However, studies have shown 
that GH treatment is also beneficial for adults with PWS, as discon-
tinuation leads to a deterioration of body composition, while con-
tinuation maintains the improved body composition acquired during 
childhood.11,12
Due to their abnormal body composition, adults with PWS are 
predisposed to develop impaired glucose tolerance (IGT) and diabe-
tes mellitus type 2 (DMT2).13 In patients developing DMT2, reported 
mean age at onset was 20 years.14 Prevalence of DMT2 in adults 
with PWS varies from 7% to 24%.14-18 GH is known to induce insu-
lin resistance,19 which might further increase the risk for IGT and 
DMT2. Studies in adults with PWS, who started GH treatment in 
adulthood, found no negative effects of GH on glucose homeostasis 
during 1 year of GH.20-22 Our previous randomized, placebo-con-
trolled, cross-over study in young adults with PWS showed a slightly 
higher fasting glucose and insulin level during 1 year of GH vs 1 year 
of placebo, but both remained well within normal ranges.23
We report the effects of 3 years of continuous GH treatment 
on glucose homeostasis in previously GH-treated young adults with 
PWS who had attained AH. We hypothesized that, during 3 years 
of GH, glucose and insulin levels would remain stable as negative 
effects of GH on glucose metabolism would be counterbalanced by 
positive effects on body composition. Furthermore, we investigated 
prevalence of IGT, DMT2 and metabolic syndrome (MS).
2  | METHODS
2.1 | Patients
We included 43 young adults participating in the Dutch Young 
Adult PWS (YAP) study, coordinated by the Dutch Growth Research 
Foundation. Inclusion criteria were as follows: (a) genetically con-
firmed diagnosis of PWS by positive methylation test; (b) GH treat-
ment for at least 5 years during childhood; (c) at least 3 years of 
continuous GH treatment after AH attainment, which was defined 
as height velocity less than 0.5 cm per 6 months and complete epi-
physeal fusion. Exclusion criteria were as follows: (a) medication to 
reduce weight (fat); (b) non-cooperative behaviour; (c) obstructive 
sleep apnea syndrome.
At attainment of AH, GH treatment had to be discontinued as 
there is no approval for GH treatment for adults with PWS. The YAP 
Study was started in 2011 to evaluate long-term effects and safety 
of GH treatment in young adults with PWS who had been treated 
with GH during childhood. Patients were included in the YAP Study 
either after participation in the Dutch PWS Cohort Study in chil-
dren4,24 or the Transition study.11,23
For patients who participated in the Dutch PWS Cohort 
Study, GH dose was lowered after AH attainment from 1 mg/m2/
day (~0.035 mg/kg/day) to 0.33 mg/m2/day (~0.012 mg/kg/day). 
Patients who participated in the Transition Study had been with-
out GH for a median duration of 1 year before restart of GH in a 
dose of 0.33 mg/m2/day. The aim of present study was to inves-
tigate effects of 3 years of GH with a stable dose. We, therefore, 
did not analyse the data of the first year after GH dose lowering 
of patients who participated in the Cohort Study, nor the data 
of the first year after GH restart of patients who participated in 
the Transition study. We chose to exclude this first year in both 
groups to eliminate influence of GH dose lowering or GH restart.
The study was approved by the Medical Ethics Committee of the 
Erasmus Medical Centre/ Sophia Children's Hospital, Rotterdam, the 
Netherlands. Written informed consent was obtained from partici-
pants and/or their legal representatives.
2.2 | Design
Open-label, prospective study investigating long-term effects and 
safety of 3 years of GH with a stable dose. All participants were ex-
amined at the Dutch PWS Reference Center in Rotterdam. Patients 
were treated with GH in a dose of 0.33 mg/m2/day (~0.012 mg/kg/
day). Dose was adjusted based on calculated body surface area 
and serum IGF-I levels between 1 and 2 SDS. Patients were ex-
amined every 6 months by the PWS team of the Dutch Growth 
Research Foundation, which is a multidisciplinary team consisting 
of a physician, nurse, psychologist, dietitian and a physiotherapist.
2.3 | Measurements
Standing height was measured in centimetres with a calibrated 
Harpenden stadiometer. Body weight was measured in kilograms on 
an electric calibrated scale (Servo Balance KA-20-150S; Servo Berkel 
Prior, Katwijk, The Netherlands). Height, weight and body mass index 
(BMI) were expressed as standard deviations scores (SDS) using 
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GrowthAnalyser version 4.0 (available at www.growt hanal yser.org), 
adjusted for sex and age according to Dutch reference values.25,26 
Systolic and diastolic blood pressure (BP) were measured once accord-
ing to standard operating procedure with an automatic blood pressure 
monitor using an appropriately sized cuff while patients were in sitting 
position. Fat mass percentage (FM%) and lean body mass (LBM) were 
measured by DXA (Lunar Prodigy type; GE Healthcare, Chalfont St. 
Giles, UK). Family history was assessed by questionnaires filled out by 
parents of participants. A positive family history for DMT2 was classi-
fied as a parent or grandparent having the condition.
2.4 | Endocrine and metabolic investigations
After overnight fasting, blood samples were collected for assess-
ment of serum IGF-I, total cholesterol, HDL cholesterol (HDLc) and 
LDL cholesterol (LDLc). A standard 75-g oral glucose tolerance test 
(OGTT) was performed every year during the 3-year study.
To evaluate overall responses to oral glucose load, apart from 
plasma levels at various time points, 120-minutes area under the 
curve (AUC) for time-concentration for glucose and insulin was 
calculated using the trapezoidal rule. Insulin/glucose ratio at 30 
and 120 minutes and homeostasis model assessment (HOMA-IR), 
calculated as insulin (µU/ml) × blood glucose (mmol/l)/22.5,27 were 
used as an index of relative insulin resistance. IGT was defined 
as a glucose level at 2 hours after glucose load between 7.8 and 
11.0 mmol/l. DMT2 was defined as a fasting glucose ≥7.0 mmol/l 
or a 2-hour glucose ≥11.1 mmol/l according to WHO guideline.28
2.5 | Assays
Blood samples were measured in the Biochemical and Endocrine 
laboratories of the Erasmus Medical Centre, Rotterdam. Glucose 
and insulin were assayed immediately. Insulin levels were as-
sessed using the Immulite 2000 assay (Siemens Healthcare 
Diagnostics) until 2018. In 2019 and 2020, insulin levels were 
assessed using Lumipulse G1200. A correction factor, provided 
by the laboratory, was used for insulin levels measured by the 
new assay. Glucose levels were determined using the Hitachi 917 
(Hitachi Device Development Center), detecting glucose levels 
between 0 and 42 mmol/l. Serum IGF-I levels were assessed using 
the Immulite 2000 (Siemens Health-care Diagnostics, Deerfield, 
IL) until 2013, with interassay CV of 6.5%. After 2013, IGF-I was 
measured using the IDS-iSYS (Immunodiagnostic Systems), with 
an interassay CV of <6.0% and intra-assay CV of <2.1%. Levels 
of IGF-I were expressed as SDS, adjusting for age and gender.29
2.6 | Metabolic syndrome
Criteria of the National Cholesterol Education Program (NCEP; Adult 
Treatment Panel III) were used to determine components of MS.30 
Patients having 3 or more of the following risk factors were classified 
as having MS: (a) Waist circumference in men greater than 102 cm, 
and in women greater than 88 cm; (b) TG >1.7 mmol/l, or treatment 
for high TG; (c) HDL-cholesterol in men <1.03, in women <1.3 mmol/l, 
or treatment to increase HDL-cholesterol; (d) systolic BP ≥ 130 or 
diastolic BP ≥85 mmHg, or treatment for hypertension; (e) Fasting 
glucose ≥5.6 mmol/l or treatment for elevated blood glucose.
2.7 | Statistics
Statistical analyses were performed with SPSS version 24.0 (SPSS 
Inc). Variables are presented as mean (standard deviation) in case 
of normally distributed variables and as median (interquartile range 
[IQR]) in case a variable was not normally distributed. Changes over 
time were calculated using linear mixed model analysis with out-
comes measured at each time point as dependent variable with an 
unstructured covariance matrix. In one patient, OGTT after 3 years 
was not performed because of development of DMT2. We therefore 
included the abnormal OGTT results during the previous years of 
this patient in mixed models to avoid bias. In case a variable was not 
normally distributed, variables were transformed, by either square 
root transformation or log transformation prior to analyses. Effects 
are presented as estimated marginal mean (95% CI). Multiple linear 
regression analyses were performed to investigate association of 
sex, family history, ethnicity, SSRT use, and GH-dose or IGF-I SDS 
with fasting and 2-hour plasma glucose, both at study start and after 
3 years. Independent samples t tests and Fisher's Exact tests were 
used to investigate differences in abnormal glucose tolerance (either 
IGT or DMT2) at start and after 3 years between groups. McNemar's 
test was used to compare the prevalence of abnormal glucose toler-
ance at start with prevalence after 3 years. Differences were consid-
ered significant if P-value was <.05.
3  | RESULTS
3.1 | Characteristics at start of the 3-year study
Forty-three young adults with PWS (18 males, 25 females) were 
included (Table 1). Median (IQR) age was 19.5 (18.7-20.7) years 
for males and 18.4 (16.9-20.8) years for females. Median (IQR) 
height was −1.0 (−1.7 to −0.3) SDS and BMI 24.5 (21.9-27.7) kg/
m2, being 0.9 (0.0-1.8) SDS. All patients had been treated with GH 
during childhood. Eighteen (41.9%) patients had a deletion, twenty 
(46.5%) an mUPD, four (9.3%) an ICD and one (2.3%) a transloca-
tion. Thirty-three patients received sex steroid replacement ther-
apy (SSRT) during the study, while ten did not. Three of the patients 
who did not receive SSRT were classified as being eugonadal, while 
seven were hypogonadal. Not prescribing SSRT in these patients 
was a mutual decision between physician and caregivers based on 
patient characteristics at that moment (eg behavioural or weight 
problems).
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3.2 | Glucose homeostasis during 3 years of 
GH treatment
Table 2 shows carbohydrate parameters during 3 years of GH treat-
ment. Estimated mean (95% CI) fasting glucose levels remained stable 
during 3 years of GH, being 4.6 (4.4-4.8) mmol/l at start and 4.7 (4.6-
4.9) mmol/l after 3 years (P = .07). Estimated mean (95% CI) fasting in-
sulin levels remained also stable, being 59.5 (45.2-75.8) pmol/l at start 
and 56.7 (45.2-69.6) pmol/l after 3 years (P = .72). Glucose at 2 hours 
after glucose load increased from 6.4 (5.8-7.0) mmol/l at start to 7.0 
(6.4-7.6) mmol/l after 3 years, but not significantly (P = .07). Other car-
bohydrate parameters also remained stable during 3 years.
Figure 1 shows plasma glucose and insulin levels before and 30, 
60, 90 and 120 minutes after glucose load at different timepoints 
during the 3-year study. All glucose and insulin levels after 3 years 
of GH were similar to levels at start. Only estimated mean (95% CI) 
fasting glucose after 2 years was significantly higher (4.8 (4.6-4.9)) 
mmol/l than at start (4.6 (4.4-4.8) mmol/l, P = .018). All other glucose 
and insulin levels at other timepoints were similar to levels at start.
3.3 | Associations with glucose metabolism
Table 3 shows the results of multiple regression analysis.
Fasting glucose both at study start and after 3 years was significantly 
associated with sex and ethnicity. Male gender was associated with 
a higher fasting glucose at study start and after 3 years (β = 0.702, 
TA B L E  1   Clinical characteristics at start of 3 year study
Number (females) 43 (25)
Genetic subtype
Deletion/mUPD/ICD/
translocation
18/20/4/1
Age at start of childhood GH 
treatment (yrs)
7.6 (5.2 to 10.1)
Age at inclusion (yrs)
Males 19.5 (18.7 to 20.7)
Females 18.4 (16.9 to 20.8)
Adult height (SDS) -1.0 (−1.7 to −0.3)
BMI (kg/m2) 24.5 (21.9 to 27.7)
BMI for age (SDS) 0.9 (0.0 to 1.8)
BMI for PWS (SDS) -1.4 (−2.0 to −0.7)
Fasting glucose (mmol/l) 4.6 (4.1 to 4.9)
Fasting insulin (pmol/l) 55.0 (35.5 to 68.0)
IGF-I SDSa  1.5 (0.6 to 2.0)
Note: Data expressed as median (IQR), mUPD, maternal uniparental 
disomy; ICD, imprinting center defect.
aIGF-I SDS was calculated according to age- and sex-matched Dutch 
references. 
TA B L E  2   Metabolic health parameters during the 3 year study
At start After 1 year After 2 years After 3 years
P-
value*
Carbohydrate data
Fasting glucose (mmol/l) 4.6 (4.4-4.8) 4.7 (4.5-4.9) 4.8 (4.6-4.9) 4.7 (4.6-4.9) .07
Glucose 2 h after glucose load 
(mmol/l)
6.4 (5.8-7.0) 6.6 (6.0-7.1) 6.8 (6.2-7.4) 7.0 (6.4-7.6) .07
AUC glucose (mmol/l * 120 min) 872.8 (807.6-938.0) 876.9 (816.2-937.5) 934.8 
(859.4-1010.2)
918.6 
(846.9-990.3)
.16
Fasting insulin (pmol/l) 59.5 (45.2-75.8) 67.6 (55.0-81.5) 63.8 (51.1-77.9) 56.7 (45.2-69.6) .72
Insulin 2 h after glucose load (pmol/l) 340.1 
(283.9-401.4)
334.2 (263.5-419.4) 317.1 (265.1-376.2) 352.8 (279.9-434.1) .72
AUC insulin (pmol/l * 120 min * 103 40.2 (34.0-47.5) 43.7 (36.4-52.4) 42.7 (38.3-47.6) 37.2 (31.5-43.9) .42
Ratio ins/gluc at 30 min 44.6 (36.0-55.2) 46.9 (39.2-56.9) 43.8 (37.6-50.9) 41.9 (34.3-51.2) .52
Ratio ins/gluc at 120 min 52.2 (42.4-64.4) 45.8 (36.8-57.0) 43.2 (34.8-53.7) 46.9 (39.6-55.6) .32
HOMA-IR 1.7 (1.3-2.2) 2.0 (1.6-2.4) 1.9 (1.5-2.4) 1.7 (1.3-2.1) .82
Blood pressure
Systolic blood pressure 119.8 (116.1-123.6) 123.8 (120.5-127.1) 122.9 (118.9-127.0) 122.3 (118.2-126.3) .36
Diastolic blood pressure 73.2 (70.5-75.9) 73.1 (71.1-75.0) 74.3 (72.0-76.5) 72.8 (70.2-75.3) .80
Lipids
Total cholesterol (mmol/l) 4.6 (4.4-4.9) 4.7 (4.4-4.9) 4.6 (4.3--4.8) 4.6 (4.4-4.8) .71
LDL cholesterol (mmol/l) 3.0 (2.7-3.2) 3.1 (2.8-3.3) 3.0 (2.8-3.2) 3.0 (2.8-3.2) .51
HDL cholesterol (mmol/l) 1.4 (1.3-1.4) 1.4 (1.3-1.5) 1.3 (1.2-1.4) 1.3 (1.3-1.4) .93
Triglycerides (mmol/l) 0.95 (0.83-1.09) 0.93 (0.82-1.05) 1.03 (0.91-1.16) 0.96 (0.83-1.12) .82
Note: Data are expressed as estimated means (95% CI). AUC, area under the curve; ins/gluc, ratio of insulin/glucose; HOMA-IR, homeostatic model 
assessment of insulin resistance.
P-value of the change during three years of GH treatment.
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P < .001 and β = 0.526, P = .008 resp.), regardless of ethnicity, FM% 
or family history, indicating that male gender results in a 0.702 mmol/l 
higher fasting glucose at study start and a 0.526 mmol/l higher fasting 
glucose after 3 years. Non-Caucasian ethnicity (eg Moroccan, Hindu 
or Surinamese) was associated with a higher fasting glucose both at 
study start and after 3 years of GH (β = 0.609, P = .011 and β = 0.654, 
P = .027, resp.). Total body FM% was also associated with fasting 
glucose, but only at start, indicating an increase of 0.023 mmol/l in 
glucose with each 1% increase in total body FM%. A model with sex, 
ethnicity, FM% and family history positive for DMT2 had an adjusted R 
square of .482 for fasting glucose at start, indicating that 48% of vari-
ability in fasting glucose levels at start is explained by these factors.
Two-hour glucose at study start was significantly associated with 
ethnicity (β = 3.485, P = .001) and total body FM% (β = 0.068, 
P = .047). After 3 years of GH, we found no significant predictors for 
2-hour glucose levels.
Adding age, SSRT use, and IGF-I SDS or GH-dose to any of the 
models did not show a significant association of these variables and 
did not improve adjusted R square values.
3.4 | IGT and DMT2 during 3 years of GH treatment
Clinical characteristics of individual patients with IGT or DMT2 dur-
ing the study are shown in Table 4.
IGT was present in 6 patients at study start. After 1 year, one of 
these patients had a normal OGTT and 9 had IGT. After 2 years, 2 pa-
tients with IGT after 1 year had returned to normal glucose tolerance 
and 10 had IGT. At the end of the 3-year study, a total of 11 patients 
met the criteria for IGT.
DMT2 was present in 1 patient at study start, based on a 
2-hour glucose level of 12.5 mmol/l. This patient did not have 
F I G U R E  1   Glucose and insulin levels during oral glucose 
tolerance test. Estimated mean glucose and insulin levels during 
OGTT at study start (black circles), after 1 year (grey circles), after 
2 years (white triangles) and after 3 years (black triangles) of 43 
young adults with PWS. *2 year vs start P-value <.05, other not 
significantly different
Study Start After 3 years
Fasting glucose 2-hour glucose Fasting glucose 2-hour glucose
β P β P β P β P
Sex −0.702 <.001 −0.219 .722 −.526 .008 1.210 .092
Ethnicity 0.609 .011 3.485 .001 .654 .027 1.640 .191
FM% 0.023 .006 0.068 .047 .014 .185 0.054 .177
Family 
history
0.235 .060 0.465 .369 .058 .704 0.368 .517
Model 
P-value
<0.001 0.001 .009 0.015
Adjusted R 
square
0.482 0.330 .239 0.219
Note: Values presented are results of multiple regression. β = unstandardized regression 
coefficient.
Sex: 1 = men 2 = women. Ethnicity: 0 = caucasian 1 = noncaucasian. Family history for diabetes 
mellitus type 2:0 = no family history 1 = positive family history.
FM% = total body fat mass percentage. Bolded p-values are significant.
TA B L E  3   Multiple regression analysis 
for fasting glucose and 2-hour glucose at 
study start and after 3 years
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polyuria or polydipsia and had a fasting glucose of 6.0 mmol/l. The 
next year, he had a 2-hour glucose level of 10.9 mmol/l, thereby 
no longer fulfilling the DMT2 criteria. After 2 years, he met the 
criteria for DMT2 again with a 2 hour glucose of 11.5 mmol/l, 
without any clinical symptoms and a fasting glucose of 6.1 mmol/l. 
A few weeks before the 3-year visit, patient was diagnosed with 
DMT2 with elevated glucose levels and symptoms of polyuria 
and polydipsia. He was started on Metformin 500 mg twice daily 
resulting in fasting glucose of 6.6 mmol/l at follow-up. At the 
end of the 3-year study, another patient had a 2-hour glucose 
of 12.1 mmol/l, without clinical symptoms and a fasting glucose 
of 4.4 mmol/l. This patient had normal glucose tolerance during 
other years of the study and continued GH treatment after. An 
OGTT was repeated at 1 year after the 3-year study and showed 
a 2-hour glucose of 4.1 mmol/l.
The prevalence of IGT or DMT2 was not significantly higher after 
3 years than at study start (P = .18). Prevalence of IGT or DMT2 
after 3 years was 50.0% in patients with a positive family history for 
DMT2 and 21.7% in patients without (P = .09). Patients with IGT or 
DMT2 had a significantly higher mean FM% of 43.3% than patients 
without, who had a mean FM% of 36.6% (P = .02).
3.5 | Metabolic syndrome
Table 2 shows BP and serum lipids during the 3-year study. Systolic 
and diastolic BP did not change during the study, neither did serum 
total cholesterol, LDLc, HDLc and triglycerides.
Table 5 shows different components of MS during the 3-year 
study. At start, 2 of 37 (5.4%) patients had three or more MS compo-
nents, thereby meeting the criteria for MS. After 3 years, this num-
ber was the same (5.3%).
4  | DISCUSSION
To our knowledge, this is the first prospective, open-label study to 
describe the effects of 3 years of continuous GH treatment with a 
TA B L E  4   Characteristics of individual patients with impaired glucose tolerance or diabetes mellitus type 2 during the study
Patient Sex Fam Ethnicity
Stage of the study
Start Study After 1 year After 2 years After 3 years
Fasting 
glucose 
(mmol/l)
2-hour 
glucose 
(mmol/l) BMI
FM% 
(%)
SSRT 
use
Fasting 
glucose 
(mmol/l)
2-hour 
glucose 
(mmol/l) BMI FM% (%)
SSRT 
use
Fasting 
glucose 
(mmol/l)
2-hour 
glucose 
(mmol/l) BMI
FM% 
(%)
SSRT 
use
Fasting 
glucose 
(mmol/l)
2-hour 
glucose 
(mmol/l) BMI FM% (%) SSRT use
1 M + noncauc 6.0 12.5 28.6 41.0 + 6.2 10.9 27.5 37.3 + 6.1 11.5 28.8 37.8 + 6.6a  T2DM 28.8 37.6 +
2 F + cauc 4.8 9.1 24.8 43.7 + 4.8 9.6 25.9 43.0 + 4.8 10.4 26.6 41.9 + 4.9 7.8 24.3 38.3 +
3 M + noncauc 5.2 7.8 19.6 27.0 + 5.3 8.2 18.6 23.9 + 5.3 7.8 18.5 22.0 + 5.3 7.8 18.9 25.0 +
4 F + cauc 4.4 8.9 22.3 37.1 + 4.7 8.3 23.5 36.7 + 5.0 6.0 23.1 34.6 + 4.1 6.6 21.7 34.5 +
5 F − noncauc 4.8 8.6 22.7 44.7 − 4.9 6.5 25.0 44.6 − 4.8 7.2 25.1 45.2 − 4.3 8.6 25.2 43.4 +
6 M − cauc 4.9 8.6 19.9 36.5 + 4.7 8.7 19.9 38.6 + 4.9 7.4 19.4 32.1 + 4.9 7.3 18.7 31.4 +
7 M + cauc 5.4 8.9 24.2 N/A + 4.5 8.2 24.6 39.4 + 4.8 N/A 25.4 40.1 + 4.9 8.1 25.9 39.2 +
8 M + cauc 4.2 6.9 19.1 28.2 + 4.6 8.2 21.8 32.5 + 4.8 8.1 22.4 32.3 + 4.4 7.2 22.3 32.1 +
9 F − cauc 4.0 5.7 24.7 42.1 − 5.0 10.0 28.4 49.1 − 4.2 10.3 27.6 48.6 − 4.9 9.5 29.3 48.0 −
10 M − cauc 4.4 7.3 20.2 18.0 + 4.4 8.3 19.9 13.1 + 4.9 5.9 20.0 20.7 + 4.6 6.1 20.0 19.0 +
11 F − cauc 3.7 5.9 20.0 29.2 + 4.0 6.2 22.1 33.7 + 4.3 7.8 22.4 37.3 + 4.1 6.9 23.1 36.4 +
12 F − cauc 4.0 3.2 21.1 37.9 + 4.6 6.0 20.9 38.2 + 4.5 8.4 22.7 42.1 + 4.3 10.5 22.2 41.4 +
13 F + cauc 5.3 5.2 24.2 42.3 − 5.0 6.7 26.0 44.1 − 5.5 9.2 24.9 43.7 − N/A 6.5 25.6 41.2 −
14 F − cauc 3.8 7.2 36.6 53.3 + 5.8 7.6 40.0 54.2 + 5.4 10.1 43.6 54.3 + 5.5 8.1 43.3 57.6 +
15 F − cauc 4.0 7.0 21.5 37.4 + 4.0 7.6 21.6 39.3 + 4.4 8.9 21.8 37.7 + 4.5 10.7 22.4 37.8 +
16 F + cauc 4.1 5.5 25.4 44.4 + N/A 6.9 26.8 44.3 + 3.9 N/A 26.2 44.7 + 4.4 12.1b  27.8 46.9 +
17 F − cauc 4.8 N/A 30.5 47.6 + 4.8 7.1 29.7 46.2 + 4.4 8.1 28.7 44.8 + 4.3 8.7 29.1 44.6 +
18 F + cauc 4.5 7.7 31.3 52.3 − 4.2 6.5 32.2 51.2 − 4.9 7.5 33.2 53.1 + 4.0 8.6 35.9 57.0 +
19 F + cauc 4.1 6.4 24.9 51.1 + N/A 4.8 25.2 48.0 + N/A N/A N/A 48.4 + 3.7 7.8 25.0 46.3 +
Note: Fam, positive family history of diabetes mellitus type 2; FM%, total body fat mass percentage; N/A, not available.
Bolded values represent glucose values ≥ 7.8 mmol/l.
aFasting plasma glucose while treated with Metformin 500 mg twice a day. 
b1 year after the end of the study 2-hour plasma glucose was 4.1 mmol/l 
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stable median dose of 0.36 mg/m2/day (~0.013 mg/kg/day), on glu-
cose homeostasis in young adults with PWS, who had attained AH 
after treatment with GH for several years during childhood. Our 
findings demonstrate that fasting and glucose-stimulated glucose 
and insulin levels during OGTT did not change during 3 years of GH 
treatment. At study start fasting glucose was associated with sex, 
TA B L E  4   Characteristics of individual patients with impaired glucose tolerance or diabetes mellitus type 2 during the study
Patient Sex Fam Ethnicity
Stage of the study
Start Study After 1 year After 2 years After 3 years
Fasting 
glucose 
(mmol/l)
2-hour 
glucose 
(mmol/l) BMI
FM% 
(%)
SSRT 
use
Fasting 
glucose 
(mmol/l)
2-hour 
glucose 
(mmol/l) BMI FM% (%)
SSRT 
use
Fasting 
glucose 
(mmol/l)
2-hour 
glucose 
(mmol/l) BMI
FM% 
(%)
SSRT 
use
Fasting 
glucose 
(mmol/l)
2-hour 
glucose 
(mmol/l) BMI FM% (%) SSRT use
1 M + noncauc 6.0 12.5 28.6 41.0 + 6.2 10.9 27.5 37.3 + 6.1 11.5 28.8 37.8 + 6.6a  T2DM 28.8 37.6 +
2 F + cauc 4.8 9.1 24.8 43.7 + 4.8 9.6 25.9 43.0 + 4.8 10.4 26.6 41.9 + 4.9 7.8 24.3 38.3 +
3 M + noncauc 5.2 7.8 19.6 27.0 + 5.3 8.2 18.6 23.9 + 5.3 7.8 18.5 22.0 + 5.3 7.8 18.9 25.0 +
4 F + cauc 4.4 8.9 22.3 37.1 + 4.7 8.3 23.5 36.7 + 5.0 6.0 23.1 34.6 + 4.1 6.6 21.7 34.5 +
5 F − noncauc 4.8 8.6 22.7 44.7 − 4.9 6.5 25.0 44.6 − 4.8 7.2 25.1 45.2 − 4.3 8.6 25.2 43.4 +
6 M − cauc 4.9 8.6 19.9 36.5 + 4.7 8.7 19.9 38.6 + 4.9 7.4 19.4 32.1 + 4.9 7.3 18.7 31.4 +
7 M + cauc 5.4 8.9 24.2 N/A + 4.5 8.2 24.6 39.4 + 4.8 N/A 25.4 40.1 + 4.9 8.1 25.9 39.2 +
8 M + cauc 4.2 6.9 19.1 28.2 + 4.6 8.2 21.8 32.5 + 4.8 8.1 22.4 32.3 + 4.4 7.2 22.3 32.1 +
9 F − cauc 4.0 5.7 24.7 42.1 − 5.0 10.0 28.4 49.1 − 4.2 10.3 27.6 48.6 − 4.9 9.5 29.3 48.0 −
10 M − cauc 4.4 7.3 20.2 18.0 + 4.4 8.3 19.9 13.1 + 4.9 5.9 20.0 20.7 + 4.6 6.1 20.0 19.0 +
11 F − cauc 3.7 5.9 20.0 29.2 + 4.0 6.2 22.1 33.7 + 4.3 7.8 22.4 37.3 + 4.1 6.9 23.1 36.4 +
12 F − cauc 4.0 3.2 21.1 37.9 + 4.6 6.0 20.9 38.2 + 4.5 8.4 22.7 42.1 + 4.3 10.5 22.2 41.4 +
13 F + cauc 5.3 5.2 24.2 42.3 − 5.0 6.7 26.0 44.1 − 5.5 9.2 24.9 43.7 − N/A 6.5 25.6 41.2 −
14 F − cauc 3.8 7.2 36.6 53.3 + 5.8 7.6 40.0 54.2 + 5.4 10.1 43.6 54.3 + 5.5 8.1 43.3 57.6 +
15 F − cauc 4.0 7.0 21.5 37.4 + 4.0 7.6 21.6 39.3 + 4.4 8.9 21.8 37.7 + 4.5 10.7 22.4 37.8 +
16 F + cauc 4.1 5.5 25.4 44.4 + N/A 6.9 26.8 44.3 + 3.9 N/A 26.2 44.7 + 4.4 12.1b  27.8 46.9 +
17 F − cauc 4.8 N/A 30.5 47.6 + 4.8 7.1 29.7 46.2 + 4.4 8.1 28.7 44.8 + 4.3 8.7 29.1 44.6 +
18 F + cauc 4.5 7.7 31.3 52.3 − 4.2 6.5 32.2 51.2 − 4.9 7.5 33.2 53.1 + 4.0 8.6 35.9 57.0 +
19 F + cauc 4.1 6.4 24.9 51.1 + N/A 4.8 25.2 48.0 + N/A N/A N/A 48.4 + 3.7 7.8 25.0 46.3 +
Note: Fam, positive family history of diabetes mellitus type 2; FM%, total body fat mass percentage; N/A, not available.
Bolded values represent glucose values ≥ 7.8 mmol/l.
aFasting plasma glucose while treated with Metformin 500 mg twice a day. 
b1 year after the end of the study 2-hour plasma glucose was 4.1 mmol/l 
Symptoms At start study After 1 year After 2 years After 3 years
Central Obesity 8/42 (19.0%) 7/41 (17.1%) 8/38 (21.1%) 6/38 (15.8%)
High triglyceride 
levels
4/41 (9.8%) 3/41 (7.3%) 5/41 (12.2%) 5/40 (12.5%)
Low HDLc 
levels
10/42 (23.8%) 11/41 (26.8%) 13/41 (31.7%) 15/40 (37.5%)
High blood 
pressure
5/41 (12.2%) 12/42 (28.6%) 12/42 (28.6%) 10/40 (25.0%)
High fasting 
glucose
1/42 (2.4%) 3/40 (7.5%) 2/42 (4.8%) 2/40 (5.0%)
Three or more 
MS-symptoms
2/37 (5.4%) 3/35 (8.6%) 4/36 (11.1%) 2/38 (5.3%)
Note: Number of patients (%) with MS-symptoms.
Abbreviation: GH, growth hormone.
TA B L E  5   Metabolic syndrome 
components during the study according to 
ATP III criteria (26)
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ethnicity and FM%, while after 3 years it was associated with sex 
and ethnicity. Two-hour glucose at start was associated with sex and 
FM%, but with none of the variables after 3 years. In multiple lin-
ear regression analysis, IGF-I or GH-dose were neither associated 
with fasting glucose nor with 2-hour glucose, both at start and after 
3 years. Blood pressure, serum lipid levels and prevalence of MS re-
mained similar during the 3-year study.
In children with PWS, we showed that fasting glucose levels 
gradually increased from 4.5 mmol/l at baseline to 4.8 mmol/l after 
8 years of GH treatment.4 Present study shows that continuation of 
treatment into adulthood does not further increase fasting glucose 
levels, which is reassuring. Our results are in line with a 2-year GH 
study in adults with PWS, showing that levels remained unchanged.31
In multiple regression analysis, we found that male gender, re-
gardless of ethnicity, FM% and family history, was associated with a 
0.7 mmol/l and 0.5 mmol/l higher fasting glucose at study start and 
after 3 years, respectively. Non-Caucasian ethnicity was associated 
with a 0.6 and 0.7 mmol/l higher fasting glucose at study start and 
after 3 years, resp., while each 1% increase in total body FM% was 
associated with a 0.02 mmol/l increase in fasting glucose at start. 
In contrast, IGF-I SDS or GH-dose were not associated with fasting 
glucose nor with 2-hour glucose, at study start and after 3 years. 
These results support our hypothesis that the beneficial effect of 
GH on maintaining a stable FM% might counterbalance the potential 
effects of GH on glucose homeostasis.
We found that patients with IGT or DMT2 had a significantly 
higher FM% than patients who did not have IGT or DMT2, and prev-
alence was higher in patients with a positive family history for DMT2 
than for those without a positive family history, albeit not statisti-
cally significant. Only 3 participants had a non-Caucasian ethnicity, 
thus it is difficult to draw conclusions. However, it is remarkable that 
all 3 patients developed either IGT or DMT2.32,33
In our study, prevalence of DMT2 was 5.1%, (or 2.6% when 
DMT2 based on a single elevated 2-hour plasma glucose level is not 
taken into account), while a prevalence of 7%-24% is described in 
literature.14-18 It is possible that the young age of our group contrib-
utes to the lower prevalence. However, one study reported a prev-
alence rate of 25% for DMT2 and a mean age at onset of 20 years.14 
As the mean age after our 3-year study was 22.5 years, the partici-
pants in our study had an age at higher risk for DMT2 development. 
We, therefore, believe that particularly the relatively low FM% and 
relatively high LBM of our study group, as a result of multiple years 
of GH treatment during childhood and the continuation of GH treat-
ment into early adulthood, are responsible for the low prevalence of 
DMT2 found in current study.
At study start 5.4% had MS and after 3 years this percentage was 
similar. Studies investigating MS in PWS are very scarce. One study 
in adults with PWS found the presence of MS in 4.8% of non-obese 
patients and 41.1% of obese patients.34 In our placebo-controlled 
GH study, none developed MS during 1 year of GH treatment, while 
one developed MS during placebo.23 As continuation of GH prevents 
deterioration of body composition, it may thereby contribute to pre-
vention of MS.11,12
Our study group had a normal median BMI of 24.5 kg/m2, being 
0.9 SDS, and a relatively healthy body composition compared to 
young adults with a classical PWS phenotype.12,35,36 We believe 
that this is the result of GH treatment during childhood together 
with multidisciplinary care from a young age onwards. We previ-
ously showed that continuation of GH in early adulthood is able to 
maintain the improved body composition.12 It is, therefore, likely that 
our results are particularly due to the more healthy condition of our 
study population and may not be applicable to patients with PWS 
who are obese. However, two studies investigating GH treatment for 
a maximum of 2 years in GH-naïve adults with PWS included patients 
with a mean BMI of 28.9 and 33.7 kg/m2. These studies also found 
no significant adverse effects of GH on glucose homeostasis.22,31 We 
expect that in the coming years more patients with PWS will be able 
to have a healthy BMI, since care for and knowledge of PWS have im-
proved during the last two decades, while GH treatment is currently 
standard treatment in children with PWS in many countries, and di-
agnosis is nowadays often made in the first months of life.
Our study did not include a control group of PWS patients not 
receiving GH treatment. We did not want to withhold GH treatment 
for a longer period in these patients, since about half of the patients 
participated previously in our randomized, placebo-controlled cross-
over GH study investigating 1 year of GH vs 1 year of placebo. That 
study showed a deterioration of body composition during discontin-
uation of GH treatment after AH11 and slightly higher fasting glucose 
and insulin levels during GH vs placebo, but levels remained within 
normal range, and glucose-stimulated glucose and insulin levels 
during OGTT were similar during GH and placebo.23 Two other stud-
ies investigated effects of 1 year of GH vs placebo in adults with PWS 
on glucose homeostasis and concluded that 1 year of GH treatment 
is safe,22,37 but one study did not record GH treatment during child-
hood37 and the other one investigated growth hormone-deficient 
adults with PWS.22
In conclusion, 3 years of continuous GH treatment with a me-
dian dose of 0.36 mg/m2/day (~0.013 mg/kg/day) in adults with 
PWS does not impair glucose homeostasis and does not lead to 
an increased prevalence of DMT2. The beneficial effect of GH on 
maintaining a healthier body composition might counterbalance the 
potential effects of GH on glucose homeostasis. Our findings show 
that longer-term GH treatment in young adults with PWS does not 
pose safety concerns regarding carbohydrate metabolism.
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